Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth

Yang, Hao; Wang, Juan; Fan, Jinhong; Zhang, Yaqi; Zhao, Junxian; Dai, Xiaojun; Liu, Qi; Shen, Yanjun; Liu, Chang; Sun, Weiyi; Sun, Yuanming

doi:10.1016/j.taap.2016.12.008

Cited by 56 publications

(26 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New agents or combinations of synergizing agents with differing or broader selectivity to inhibit a variety of angiogenic pathways, or targeting agents to specific populations with a sensitizing mutation may potentially overcome initial or acquired resistance to initial antiangiogenic inhibitor treatment. Some agents are already demonstrating encouraging results in the laboratory and clinic (13,36,43,(77)(78)(79).…”

Section: Future Directionsmentioning

confidence: 99%

The Role of Angiogenesis in Hepatocellular Carcinoma

Morse

Sun

Kim

et al. 2019

Clinical Cancer Research

434

295

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) accounts for about 90% of all primary liver cancers and is the second leading cause of cancer-related deaths worldwide. The hypervascular nature of most HCC tumors underlines the importance of angiogenesis in the pathobiology of these tumors. Several angiogenic pathways have been identified as being dysregulated in HCC, suggesting they may be involved in the development and pathogenesis of HCC. These data provide practical targets for systemic treatments such as those targeting the vascular endothelial growth factor receptor and its ligand. However, the clinical relevance of other more recently identified angiogenic pathways in HCC pathogenesis or treatment remains unclear. Research into molecular profiles and validation of prognostic or predictive biomarkers will be required to identify the patient subsets most likely to experience meaningful benefit from this important class of agents.

show abstract

Section: Future Directionsmentioning

confidence: 99%

The Role of Angiogenesis in Hepatocellular Carcinoma

Morse

Sun

Kim

et al. 2019

Clinical Cancer Research

434

295

View full text Add to dashboard Cite

show abstract

“…The protein sample was extracted according to a previously reported method [16]. In brief, cold radioimmunoprecipitation buffer containing protease inhibitor was used to lyse the cells.…”

Section: Western Blotmentioning

confidence: 99%

Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B

Zhang

Wang

2020

Virol J

View full text Add to dashboard Cite

Background: The present study aims to explore the functions of circular RNA hsa_circ_0004812 in chronic hepatitis B (CHB) and its underlying molecular mechanisms. Methods: The expression of circular RNA (circRNA)_0004812 was examined using qRT-PCR and Western blot in blood and liver tissues from CHB patients and healthy volunteers. In the in vitro study, the expression levels of circular RNA hsa_circ_0004812, miR-1287-5p, interferon (IFN)-α, IFN-β were determined using qRT-PCR and Western blotting in HBV-infected hepatoma cells, respectively. Luciferase and biotin pull-down assays were used to investigate the interactions between miR-1287-5p and circ_0004812. Results: Levels of circ_0004812 were upregulated in CHB patients and HBV-infected hepatoma cells. Knockdown of circ_0004812 increased the expression of IFN-α and IFN-β in HBV-infected Huh7 cells. MiR-1287-5p was identified as a target of circ_0004812 whose overexpression inhibited the expression of miR-1287-5p. Additionally, circ_0004812 promoted the expression of Follistatin-related protein (FSTL) 1 through inhibiting miR-1287-5p. Circ_0004812/miR-1287-5p/FSTL1 axis regulated HBV-induced immune suppression. Conclusion: Circ_0004812 was identified as a potential target for CHB infection. Circ_0004812 promoted the expression of FSTL1 by inhibiting miR-1287-5p.

show abstract

“…The role of PI3K/AKt/mTOR pathway in HCC can be summarized as follows: (1) promoting the formation of tumor blood vessels: PI3K/AKt/mTOR pathway participates in the formation of blood vessels in tumor mainly through two ways: PI3K/AKt signaling pathway can activate the cyclooxygenase 2 (COX-2), which is a key enzyme that catalyzes the synthesis of prostaglandin-like substances, thereby promoting the angiogenesis of liver cancer [53] . Hypoxia and growth factors can induce the expression of hypoxia inducible factor 1α (HIF-1α) [54] , the downstream blood vessels endothelial growth factor (VEGF) transcription [55] . The PI3K/AKt pathway activation can up-regulate the expression of HIF-1α and VEGF, thus making endothelial cell migrate to form new blood vessels; (2) promoting tumor invasion and metastasis: Johnson and Tee [56] have shown that PI3K/ AKt/mTOR activation can make the downstream molecules p70s6k phosphorylated to make actin filament remodel and to enhance the ability of tumor cells to move, thus increasing the invasion and metastasis of cancer cells.…”

Section: Signaling Pathwaysmentioning

confidence: 99%

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Chen¹,

Hu²,

Xu³

et al. 2018

View full text Add to dashboard Cite

Primary liver cancer is one of the leading causes of cancer-related deaths worldwide. China has more than 55% liver cancer cases globally. The development of hepatocellular carcinoma (HCC) was caused by a variety of risks factors, including chronic inflammation by virus, alcohol consumption and non-alcoholic steatohepatitis. Emerging evidence has notarized inflammation as a critical component of HCC progression. The development of HCC is a multistep process which may originate from liver chronic injury and inflammation to subsequent fibrosis and/or cirrhosis and finally HCC. A large number of studies indicate that chemokines and cytokines are candidates linking molecules between inflammation and liver cancer. Here, we will describe a few of the key cytokines and chemokines and signal pathways which are involved in the inflammation of HCC. Inhibitors of inflammation for the prevention and overcoming antitumor immunity for treatment of liver cancer are promising candidates for the future management of patients with HCC.

show abstract

Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth

Cited by 56 publications

References 63 publications

The Role of Angiogenesis in Hepatocellular Carcinoma

The Role of Angiogenesis in Hepatocellular Carcinoma

Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B

Understanding the inflammation-cancer transformation in the development of primary liver cancer

Contact Info

Product

Resources

About